Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$21.79 - $32.15 $100,430 - $148,179
-4,609 Reduced 28.06%
11,819 $341,000
Q4 2023

Feb 14, 2024

BUY
$14.05 - $23.44 $230,813 - $385,072
16,428 New
16,428 $376,000
Q2 2022

Aug 15, 2022

BUY
$7.06 - $25.52 $76,502 - $276,534
10,836 New
10,836 $86,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.25B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Corton Capital Inc. Portfolio

Follow Corton Capital Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Corton Capital Inc., based on Form 13F filings with the SEC.

News

Stay updated on Corton Capital Inc. with notifications on news.